Tech Company Financing Transactions
Armo Bio Sciences Funding Round
Armo Bio Sciences closed a $30 million Series B funding round on 5/28/2014. Investors included NanoDimension, DAG Ventures and Kleiner Perkins Caufield & Byers.
Transaction Overview
Company Name
Announced On
5/28/2014
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Series B
Investors
NanoDimension (Lead Investor)
Kleiner Perkins Caufield & Byers (Beth Seidenberg)
OrbiMed (Carl Gordon)
Proceeds Purpose
We intend to use the Series B funding to complete several expansion cohorts of our Phase 1 study of AM0010, including drug combination cohorts designed to evaluate the safety and tolerability of AM0010 in combination with standard of care and with other immunotherapy drugs. We expect results from the dose escalation part of the study by mid-2014.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
575 Chesapeake Dr.
Redwood City, CA 94063
USA
Redwood City, CA 94063
USA
Phone
Undisclosed
Website
Email Address
Overview
ARMO Biosciences is a biotechnology company that develops immune modulatory biologic therapeutics.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Peter Van Vlasselaer
Chief Medical Officer
Joseph Leveque
Founder
Martin Oft
VP - Bus. Development
Scott Ogg
VP - Operations
Russell Kawahata
Browse more venture capital transactions:
Prev: 5/28/2014: Distil Networks venture capital transaction
Next: 5/28/2014: MedCPU venture capital transaction
Share this article
News on VC Transactions
Our team works diligently to document every notable VC transaction. VC transactions on this site come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs